GE HealthCare introduced new capabilities to its Intelligent Radiation Therapy (iRT) platform at the ASTRO 2025 Annual Meeting, aiming to reduce delays in radiation therapy and streamline increasingly complex oncology workflows.
The company’s latest iRT version adds AI-enabled tools and broader system integration to support faster, more efficient planning and delivery of radiation therapy. Among the updates is a new theranostics module designed to manage the full workflow for radiopharmaceutical-based treatments.
Radiation therapy, which nearly 60% of cancer patients receive, often involves fragmented workflows that can delay treatment by weeks. GE HealthCare says early adopters of iRT have reduced the time from simulation to treatment planning from seven days to seven minutes through integration with RayStation by RaySearch Laboratories.
Ensure critical devices are ready to go
Keep biomedical devices ready to go, so care teams can be ready to care for patients. GE HealthCare’s ReadySee™ helps overcome frustrations due to lack of network and device visibility, manual troubleshooting, and downtime.
New features include analytics dashboards for administrators, staff scheduling tools, AI-based auto-segmentation of organs-at-risk using GE’s MR Contour DL and third-party solutions, and integration with a virtual reality training and patient education app. The platform is vendor-neutral and connects with commonly used EMRs, oncology information systems, and other interoperability frameworks.
“We are transforming the radiation therapy experience for patients and clinicians with our Intelligent Radiation Therapy solution, helping clinicians move from diagnosis to treatment in minutes, not days,” said Ben Newton, general manager for oncology solutions at GE HealthCare.
The newly introduced iRT functionality for theranostics offers a guided workflow for patient assessment, scheduling, dosing, and clinical review. It is designed to address the procedural and communication challenges in radioligand therapies.
“Miami Cancer Institute is pleased to collaborate with GE HealthCare on iRT, an innovative solution designed to address the rapidly evolving landscape of radiopharmaceuticals,” said Dr. Ranjini Tolakanahalli, director of photon physics at Miami Cancer Institute.
GE HealthCare is also showcasing updates to MIM Maestro and the iRT MR Direct solution, which supports MR-only planning for brain, head and neck, and pelvic cancers.
link